Table 2 Univariate and multivariable proportional hazards model for relapse-free and overall survival for SUCCESS serum samples
From: Methylation patterns in serum DNA for early identification of disseminated breast cancer
| Characteristic | Univariate analyses | |||
| Relapse-free survival | Overall survival | |||
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Menopausal status, post vs pre | 1.323 (0.750–2.333) | 0.335 | 2.872 (1.164–7.086) | 0.022 |
| Tumor size, T2-T4 vs T1 | 2.268 (1.187–4.332) | 0.013 | 3.881 (1.343–11.218) | 0.012 |
| Lymph node involvement, N1-3 vs N0 | 1.645 (0.861–3.142) | 0.132 | 3.012 (1.045–8.683) | 0.041 |
| Estrogen receptor (ER) status, ER- vs ER+ | 1.316 (0.999–1.734) | 0.051 | 1.333 (0.918–1.934) | 0.131 |
| Progesterone receptor (PR) status, PR- vs PR+ | 1.180 (0.897–1.554) | 0.237 | 1.219 (0.839–1.772) | 0.298 |
| HER2 status, HER2+ vs HER2- | 1.907 (0.858–4.241) | 0.113 | 1.789 (0.618–5.178) | 0.283 |
| Grading, G3 vs G1/2 | 1.079 (0.623–1.868) | 0.786 | 1.129 (0.535–2.384) | 0.75 |
| CTCs before chemo, CTC+ vs CTC- | 3.666 (2.110–6.368) | <0.0001 | 5.681 (2.686–12.014) | <0.0001 |
| CTCs after chemo, CTC+ vs CTC- | 1.401 (0.757–2.592) | 0.283 | 1.467 (0.646–3.331) | 0.36 |
| EFC#93 before chemo, EFC#93+ vs EFC#93- | 4.912 (2.613–9.233) | <0.0001 | 7.689 (3.518–16.804) | <0.0001 |
| EFC#93 after chemo, EFC#93+ vs EFC#93- | 1.913 (0.927–3.949) | 0.079 | 1.807 (0.673–4.853) | 0.24 |
| Multivariable analyses | ||||
| Relapse-free survival | Overall survival | |||
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Menopausal status | 1.294 (0.728–2.302) | 0.379 | 2.688 (1.070–6.750) | 0.035 |
| Tumor size | 1.763 (0.914–3.401) | 0.091 | 2.945 (1.009–8.597) | 0.048 |
| Lymph node involvement | 1.442 (0.750–2.775) | 0.273 | 2.242 (0.765–6.566) | 0.141 |
| CTCs before chemo | 2.847 (1.613–5.024) | 0.0003 | 3.623 (1.681–7.812) | 0.001 |
| EFC#93 before chemo | 3.782 (1.965–7.281) | <0.0001 | 5.973 (2.634–13.542) | <0.0001 |